Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer
Sponsor: American Heart Association
Listed as NCT02666378, this observational or N/A phase trial focuses on Breast Cancer and remains completed. Sponsored by American Heart Association, it has been updated 13 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Oct 2024 — Present [monthly]
Completed
Status: Recruiting → Completed
-
Sep 2024 — Oct 2024 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Aug 2023 — Jul 2024 [monthly]
Recruiting
Status: Unknown Status → Recruiting · Phase: NA → None
-
Sep 2022 — Aug 2023 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
▶ Show 8 earlier versions
-
Mar 2021 — Sep 2022 [monthly]
Recruiting NA
-
Jan 2021 — Mar 2021 [monthly]
Recruiting NA
-
May 2020 — Jan 2021 [monthly]
Recruiting NA
-
Jul 2019 — May 2020 [monthly]
Recruiting NA
-
Jan 2019 — Jul 2019 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Jan 2019 [monthly]
Not Yet Recruiting NA
-
Feb 2017 — Jun 2018 [monthly]
Not Yet Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- American Heart Association
- Beth Israel Deaconess Medical Center
- Dana-Farber Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .